COMPASS PATHWAYS PLC -

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

26 May 2023 16:00:00 By Nasdaq GlobeNewswire

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

26 May 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

11 May 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

03 May 2023 16:01:00 By Nasdaq GlobeNewswire

American Medical Association to Issue First New Code for Psychedelic Therapies

02 May 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference

10 Apr 2023 10:10:13 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

02 Mar 2023 10:23:22 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

24 Feb 2023 12:01:00 By Nasdaq GlobeNewswire

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

08 Dec 2022 04:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

28 Nov 2022 16:01:00 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

03 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

03 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

26 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

12 Oct 2022 11:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

04 Oct 2022 09:05:40 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

19 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in three upcoming investor events

01 Sep 2022 08:06:21 By Nasdaq GlobeNewswire

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

04 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

02 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

28 Jul 2022 04:00:00 By Nasdaq GlobeNewswire